Clinical TrialID 3769
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy
NCT04646447
GRIN Related Disorders
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 3769
- Evidence Id
- 3769
- Core Evidence Id
- 3769
- Source Clinical Trial Id
- 3743
- Herb2 Clinical Trial Id
- HBCT003743
- Nct Id
- NCT04646447
- Title
- Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy
- Status
- Phase
- Study Result
- No
- Study Condition
- GRIN Related Disorders
- Study Type
- Interventional
- Study Design
- Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DIETARY_SUPPLEMENT: L-serine
- Intervention Allocation
- Intervention Model
- Single_Group
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Child, Adult
- Enrollment
- 20
- Outcome Measure
- Number of participants with any adverse event, Dose tolerability is based on subject interviews and scheduled assessment evaluating the presence or absence of adverse events. The presence of adverse events will be collected according the doses of L-serine: 250 mg / kg / day and 500 mg / kg / day. Pre-existing conditions (present before intake of study nutreceutical) or pretreatment AEs (onset before intake of study nutraceutical) are considered concomitant diseases and should not be recorded as AEs but should be recorded on the concomitant diseases eCRF page. However, if the subject experiences a worsening, increased frequency, or complication of such a concomitant disease, the worsening, increased frequency, or complication should be recorded as an AE., up to 12 months|Change in mental age with Vineland Adaptive Behavior Scales (VABS) (Vineland-3), Exploring the following domains: Communication, Daily Living Skills, Socialization and motor Skills (gross and fine) Once obtained the mental age equivalent, the neuropsychologist test or battery to assess the neurodevelopment will be selected, Baseline (approximately 3 months prior to intervention), 0 months (start treatment) and 3, 6 and 12 months post intervention|Change in bayley Scales of Infant and Toddler Development (BSID), The Bayley Scales of Infant and Toddler Development (BSID-III) are a set of standardized rating scales, which enable us to assess the cognition, receptive language, expressive language, fine motor and gross motor of children between 1 and 42 months. The Cognitive battery, which consists on the evaluation of the following items: visual perception, attention, memory, objects manipulation and exploration, communication skills and verbal comprehension. Bayley III has a raw score, scale score, composite score, and growth percentile score. All of these scores will be given in the study. A higher score means improvement is better. The high score for cognition is 91, 48 for receptive language, 49 for expressive language, 66 for fine motor and 72 for gross motor evaluation., Baseline (approximately 3 months prior to intervention), 0 months (start treatment) and 3, 6 and 12 months post intervention|Efficiency of the treatment measured by change in the cognitive assessment (Wechsler Intelligence Scale., If the mental age is more than 42 months will be considering the followings neuropsychologist test: Specific test will be chosen according the age of the children. 1. The Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV): Age range: 2 years 6 months to 7 years 7 months. An index score can range from 40 to 160. A higher score means improvement is better. 2. The Wechsler Intelligence Scale for Children (WISC V): Age range: Children aged 6:0-16:11. It has 5 composite scores and a Full-Scale Intelligence Quotient (FSIQ) is generated based on seven subtests. The primary index scores range from 45 to 155; the FSIQ ranges from 40 to 160. A higher score means improvement is better. 3. The Wechsler Adult Intelligence Scale (WAIS-IV): Age range: 16 years to 90 years, 11 months. The test has 15 subtests, 10 of which are core subtests that are usually used to measure the four index scores and the FSIQ. A higher score means improvement is better., Baseline (approximately 3 months prior to intervention), 0 months (start treatment) and 3, 6 and 12 months post intervention|Change in the Achenbach System of Empirically Based Assessment (ASEBA) System of Empirically Based Assessment (ASEBA)+, The Achenbach System of Empirically Based Assessment (ASEBA) for parents and teachers offers a comprehensive approach to assessing adaptive and maladaptive functioning, Baseline (approximately 3 months prior to intervention), 0 months (start treatment) and 3, 6 and 12 months post intervention|Change in Gross Motor Function Measure-88, Items span the spectrum of gross motor activities in five dimensions. A: Lying and Rolling, B: Sitting C: Crawling and Kneeling, D: Standing, and E: Walking, Running and Jumping., -3 months, 0 months (start treatment), 3 months, 6 months, 12 months|Change in Social Communication Questionnaire (SCQ), Evaluates communication skills and social functioning in children who may have autism or autism spectrum disorders and The SCQ is a 40-item survey where each question is a 'yes' or 'no' answer. The total possible range of scores is 0-39 (verbal children) or 0-33 (non-verbal children) with higher scores indicative of greater frequency of symptoms. They are completed by parents or other primary caregiver., Baseline (approximately 3 months prior to intervention), 0 months (start treatment) and 3, 6 and 12 months post intervention|Change in the Sleep Disturbance Scale for Children (SDSC), The Sleep Disturbance Scale for Children (SDSC) is a 27-item inventory rated on a 5 point Likert-type scale. 0 = least severe and 5 = most severe The instrument's purpose is to categorize sleep disorders in children. As well as giving an overall score the instrument uses five subdomains: disorders of initiating and maintaining sleep, sleep breathing disorders, disorders of arousal, sleep-wake transition disorders, disorders of excessive somnolence, and sleep hyperhidrosis., Baseline (approximately 3 months prior to intervention), 0 months (start treatment) and 3, 6 and 12 months post intervention
- Sponsor Collaborator
- Fundació Sant Joan de Déu|Hospital Sant Joan de Deu
- Funded By
- OTHER
- Location
- Hospital Sant Joan de Deu, Barcelona, Esplugues De Llobregat, Barcelona, 08950, Spain
- Other Id
- PIC-29-20
- Start Date
- 2020-07-30
- Primary Completion Date
- 2021-08-31
- Completion Date
- 2022-05-31
- First Posted
- 2020-11-30
- Results First Posted
- Last Update Posted
- 2020-11-30
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT04646447
- Title Cn
- Title En
- Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy
- Bilingual Status
- semi_complete